|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Santa-Maria CA, Nye L, Mutonga MB, Jain S
and Gradishar WJ: Management of Metastatic HER2-positive breast
cancer: Where are we and where do we go from here? Oncology
(Williston Park). 30:148–155. 2016.PubMed/NCBI
|
|
3
|
Puglisi F, Rea D, Kroes MA and Pronzato P:
Second-line single-agent chemotherapy in human epidermal growth
factor receptor 2-negative metastatic breast cancer: A systematic
review. Cancer Treat Rev. 43:36–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerratana L, Fanotto V, Bonotto M,
Bolzonello S, Minisini AM, Fasola G and Puglisi F: Pattern of
metastasis and outcome in patients with breast cancer. Clin Exp
Metastasis. 32:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sihto H, Lundin J, Lundin M, Lehtimäki T,
Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T,
Isola J, et al: Breast cancer biological subtypes and protein
expression predict for the preferential distant metastasis sites: A
nationwide cohort study. Breast Cancer Res. 13:R872011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu
J, Klijn JG, Foekens JA and Martens JW: Subtypes of breast cancer
show preferential site of relapse. Cancer Res. 68:3108–3114. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berman AT, Thukral AD, Hwang WT, Solin LJ
and Vapiwala N: Incidence and patterns of distant metastases for
patients with early-stage breast cancer after breast conservation
treatment. Clin Breast Cancer. 13:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heitz F, Harter P, Lueck HJ,
Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and
du Bois A: Triple-negative and HER2-overexpressing breast cancers
exhibit an elevated risk and an earlier occurrence of cerebral
metastases. Eur J Cancer. 45:2792–2798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Metzger-Filho O, Sun Z, Viale G, Price KN,
Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates
AS, Goldhirsch A and Cardoso F: Patterns of Recurrence and outcome
according to breast cancer subtypes in lymph node-negative disease:
Results from international breast cancer study group trials VIII
and IX. J Clin Oncol. 31:3083–3090. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paluch-Shimon S, Ben-Baruch N, Wolf I,
Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane
R and Kaufman B: Hormone receptor expression is associated with a
unique pattern of metastatic spread and increased survival among
HER2-overexpressing breast cancer patients. Am J Clin Oncol.
32:504–508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Minisini AM, Moroso S, Gerratana L,
Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C,
Fasola G and Puglisi F: Risk factors and survival outcomes in
patients with brain metastases from breast cancer. Clin Exp
Metastasis. 30:951–956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sperduto PW, Kased N, Roberge D, Chao ST,
Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, et al: The
effect of tumor subtype on the time from primary diagnosis to
development of brain metastases and survival in patients with
breast cancer. J Neurooncol. 112:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hammond ME, Hayes DF, Wolff AC, Mangu PB
and Temin S: American society of clinical oncology/college of
american pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Oncol Pract. 6:195–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kimbung S, Loman N and Hedenfalk I:
Clinical and molecular complexity of breast cancer metastases.
Semin Cancer Biol. 35:85–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thurlimann B and Senn HJ; Panel members, : Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Onco. 22:1736–1747. 2011.
View Article : Google Scholar
|
|
20
|
Ongaro E, Gerratana L, Cinausero M,
Pelizzari G, Poletto E, Giangreco M, Andreetta C, Pizzolitto S, Di
Loreto C, Minisini AM, et al: Comparison of primary breast cancer
and paired metastases: Biomarkers discordance influence on outcome
and therapy. Future Oncol. 14:849–859. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Killelea BK, Gallagher EJ, Feldman SM,
Port E, King T, Boolbol SK, Franco R, Fei K, Le Roith D and Bickell
NA: The effect of modifiable risk factors on breast cancer
aggressiveness among black and white women. Am J Surg. 218:689–694.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujii K, Watanabe R, Ando T, Kousaka J,
Mouri Y, Yoshida M, Imai T, Nakano S and Fukutomi T: Alterations in
three biomarkers (estrogen receptor, progesterone receptor and
human epidermal growth factor 2) and the Ki67 index between primary
and metastatic breast cancer lesions. Biomed Rep. 7:535–542.
2017.PubMed/NCBI
|
|
23
|
Soni A, Ren Z, Hameed O, Chanda D, Morgan
CJ, Siegal GP and Wei S: Breast cancer subtypes predispose the site
of distant metastases. Am J Clin Pathol. 143:471–478. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, He W and Zhang S: Seeking for
correlative genes and signaling pathways with bone metastasis from
breast cancer by integrated analysis. Front Oncol. 9:1382019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jones DH, Nakashima T, Sanchez OH,
Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R,
Hojilla CV, et al: Regulation of cancer cell migration and bone
metastasis by RANKL. Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Acharya S, Yao J, Li P, Zhang C, Lowery
FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, et al:
Sphingosine-kinase-1 signaling promotes metastasis of
triple-negative breast cancer. Cancer Res. 79:4211–4226. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan
M, Zhou X, Xia W, Hortobagyi GN, Yu D and Hung MC: Upregulation of
CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell.
6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu W, Chen J, Ye W, Li X and Zhang J:
Fatty liver decreases the risk of liver metastasis in patients with
breast cancer: A two-center cohort study. Breast Cancer Res Treat.
166:289–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park HS, Kim S, Kim K, Yoo H, Chae BJ, Bae
JS, Song BJ and Jung SS: Pattern of distant recurrence according to
the molecular subtypes in Korean women with breast cancer. World J
Surg Oncol. 10:42012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carvalho ST, Stiepcich MM, Fregnani JH,
Nonogaki S, Rocha R and Soares FA: Evaluation of prognostic factors
in stage IIA breast tumors and their correlation with mortality
risk. Clinics (Sao Paulo). 66:607–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang C, Wang S, Israel HP, Yan SX,
Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky
K and Connolly EP: Higher locoregional recurrence rate for
triple-negative breast cancer following neoadjuvant chemotherapy,
surgery and radiotherapy. Springer Plus. 4:3862015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giuli MV, Giuliani E, Screpanti I,
Bellavia D and Checquolo S: Notch signaling activation as a
hallmark for triple-negative breast cancer subtype. J Oncol.
2019:87070532019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Press DJ, Miller ME, Liederbach E, Yao K
and Huo D: De novo metastasis in breast cancer: Occurrence and
overall survival stratified by molecular subtype. Clin Exp
Metastasis. 34:457–465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bonotto M, Gerratana L, Poletto E, Driol
P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa
FE, et al: Measures of outcome in metastatic breast cancer:
Insights from a real-world scenario. Oncologist. 19:608–615. 2014.
View Article : Google Scholar : PubMed/NCBI
|
